<DOC>
	<DOCNO>NCT00342056</DOCNO>
	<brief_summary>This study examine DNA cancer patient previously treat Gleevec look variation ( mutation ) ABCG2 gene may render drug less effective certain patient . Gleevec use treat chronic myeloid leukemia gastrointestinal tumor . Although patient respond treatment , many advance disease develop resistance drug . It think patient resistance result action protein cause Gleevec pump cell , reduce usefulness . Patients enrol clinical trial Gleevec National Cancer Institute participate institution eligible study . DNA patient ' blood sample analyze ABCG2 gene correlate clinical data , patient 's age , race , disease state , weight , height , body surface area . It also look drug dose , often drug give , duration treatment , side effect medication take .</brief_summary>
	<brief_title>Role Gene Variation Effectiveness Gleevec Treatment</brief_title>
	<detailed_description>ABCG2 , also know breast cancer resistance protein ( BCRP ) , ATP-binding cassette ( ABC ) transporter show confer resistance several drug , include mitoxantrone topotecan . Gleevec ( imatinib mesylate ) recently identify substrate ABCG2 . The expression ABCG2 human jejunum show high expression MDR1 , encode P-glycoprotein . Therefore , plausible oral bioavailability Gleevec could dependent extent transport . A single nucleotide polymorphism ( C421A ) identify ABCG2 show vitro result functional inactivation transporter protein . In study , relationship genotype ABCG2 pharmacokinetics side effect retrospectively explore patient cancer previously enrol clinical trial Gleevec .</detailed_description>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>INCLUSION CRITERIA : In retrospective study , cancer patient enrol IRB approve clinical trial Gleevec National Cancer outside institution eligible , provide consent original consent form . EXCLUSION CRITERIA :</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Transporter Proteins</keyword>
	<keyword>Drug Exposure</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Retrospective</keyword>
	<keyword>Cancer</keyword>
</DOC>